SAN ANTONIO--(Innovative Trauma Care (ITC), an early-stage medical device firm focused on developing point of injury solutions for trauma, first responder and military medicine applications, has received regulatory approval from Health Canada for commercial sale of its first product, the ITClampTM Hemorrhage Control System in Canada. The product will be available in the fourth quarter of 2012 for Canadian medical professionals.)--
“As a company that is rooted in Canada, we are proud that our home country is the first to recognize the benefits that the ITClamp can provide in saving patients’ lives.”
The ITClamp was designed to address massive hemorrhage – a leading cause of death in traumatic injury – by controlling critical bleeding in as little as five seconds. The clamping device works by sealing the skin closed to create a temporary pool of blood under pressure, which forms a stable clot until the wound can be surgically repaired.
Health Canada is the Federal department in Canada that reviews medical devices to assess their safety and effectiveness before being authorized for sale in Canada. ITC expects regulatory approval from the European Union in late 2012 and US clearance from the FDA in 2013.
Innovative Trauma Care’s CEO and founder, Dr. Dennis Filips, said, “As a company that is rooted in Canada, we are proud that our home country is the first to recognize the benefits that the ITClamp can provide in saving patients’ lives.”
Incorporated in 2010 and based in Edmonton, Canada with a US headquarters in San Antonio, Texas, Innovative Trauma Care is addressing unmet needs in the field of emergency medicine by developing, manufacturing, and commercializing point of injury solutions to treat common causes of preventable death in traumatic injury scenarios.